A computational model of induced pluripotent stem-cell derived cardiomyocytes for high throughput risk stratification of KCNQ1 genetic variants

Divya C. Kernik¹, Pei-Chi Yang¹, Junko Kurokawa², Joseph C. Wu³, Colleen E. Clancy¹*

¹ Department of Physiology and Membrane Biology, Department of Pharmacology, School of Medicine, University of California, Davis, Davis, California, United States of America, ² Department of Bio-Informational Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan, ³ Stanford Cardiovascular Institute, Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, United States of America

* ceclancy@ucdavis.edu

Abstract

In the last decade, there has been tremendous progress in identifying genetic anomalies linked to clinical disease. New experimental platforms have connected genetic variants to mechanisms underlying disruption of cellular and organ behavior and the emergence of proarrhythmic cardiac phenotypes. The development of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) signifies an important advance in the study of genetic disease in a patient-specific context. However, considerable limitations of iPSC-CM technologies have not been addressed: 1) phenotypic variability in apparently identical genotype perturbations, 2) low-throughput electrophysiological measurements, and 3) an immature phenotype which may impact translation to adult cardiac response. We have developed a computational approach intended to address these problems. We applied our recent iPSC-CM computational model to predict the proarrhythmic risk of 40 KCNQ1 genetic variants. An I\textsubscript{KS} computational model was fit to experimental data for each mutation, and the impact of each mutation was simulated in a population of iPSC-CM models. Using a test set of 15 KCNQ1 mutations with known clinical long QT phenotypes, we developed a method to stratify the effects of KCNQ1 mutations based on proarrhythmic markers. We utilized this method to predict the severity of the remaining 25 KCNQ1 mutations with unknown clinical significance. Tremendous phenotypic variability was observed in the iPSC-CM model population following mutant perturbations. A key novelty is our reporting of the impact of individual KCNQ1 mutant models on adult ventricular cardiomyocyte electrophysiology, allowing for prediction of mutant impact across the continuum of aging. This serves as a first step toward translating predicted response in the iPSC-CM model to predicted response of the adult ventricular myocyte given the same genetic mutation. As a whole, this study presents a new computational framework that serves as a high throughput method to evaluate risk of genetic mutations based-on proarrhythmic behavior in phenotypically variable populations.
Author summary

In the last decade, there has been tremendous progress in identifying genetic mutations linked to clinical diseases, such as cardiac arrhythmia. Many experimental platforms have been developed to study this link, including induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). iPSC-CMs are patient-derived cardiac cells which allow for the study of genetic variants within a patient-specific context. However, experimentally iPSC-CMs have certain limitations, including: (1) they exhibit variability in behavior within cells that are apparently genetically identical, and (2) they are immature compared to adult cardiac cells. In our study, we have developed a computational approach to model 40 genetic variants in the KCNQ1 gene and predict the proarrhythmic risk of each variant. To do this, we modeled the ionic current determined by KCNQ1, $I_{Ks}$, to fit experimental data for each mutation. We then simulated the impact of each mutation in a population of iPSC-CMs, incorporating variability across the population. We also simulated each variant in an adult cardiac cell model, providing a link between iPSC-CM response to mutants and adult cardiac cell response to the same mutants. Overall, this study provides a new computational framework to evaluate risk of genetic mutations based-on proarrhythmic behavior diverse populations of iPSC-CM models.

Introduction

The impact of genetic variation on cardiac electrical activity is increasingly understood through identification and characterization of genetic anomalies in cardiac ion channel encoding genes, and their causal relationship to patient phenotype [1–3]. Understanding how variation in cardiac genes impacts cardiac function is important for treating and understanding complex genetic and inherited disorders, distinguishing between benign and hazardous variants of unknown significance (VUS), and revealing differential responses to drug interventions [4, 5]. For example, mutations in the KCNQ1 gene have been linked to cardiac repolarization abnormalities, including long QT syndrome (LQTS) [6], although the impact of specific mutations is often unknown. Genetic defects in KCNQ1 linked to LQTS, known as LQT1, cause a decrease in the slow delayed rectifier potassium current ($I_{Ks}$), resulting in prolongation of the action potential at the cellular level and clinical prolongation of the QT interval [7].

Induced pluripotent stem-cell derived cardiomyocytes (iPSC-CMs) have been utilized as a novel \textit{in vitro} tool to reveal insights into patient-specific disease mechanisms [8–10]. iPSC-CMs constitute a powerful approach because they are patient-derived cells that retain the genetic information of the donor patients or cell line and can show patient-specific genotype-phenotype relationships, including genetic disease phenotypes such as LQT1 [11–16]. iPSC-CMs also have unique potential to provide a human physiological context to evaluate the impact of a genetic mutation in an \textit{in vitro} human cardiac environment [17]. iPSC-CMs have further proven to be a powerful tool in evaluating VUS and linking genetic variants to their clinical outcomes [18, 19]. However, evaluating the true significance of VUS mutations will require more than a patient-specific understanding, as a VUS may result in varied phenotypes both within families and across populations [20, 21]. Currently, evaluation of VUS in iPSC-CMs population studies are limited by the relatively low throughput approach of patch-clamp evaluation of cell-specific response [18, 19, 22]. Understanding how variants differentially impact the diverse range of patient genetics across a population will be critical to understanding the clinical significance and treatment of genetic disorders.
The development of computational models that incorporate parameter variation, as a means to explore all possible population phenotypes, provide a high-throughput way to analyze cardiomyocyte phenotypic variability [23–25]. Population-based modeling can link known effects of genetic mutations in a single patient, or an experimental cell model, to the differential effect of a genetic mutation across a population of patients [26, 27], depending on the collective expression of all cardiac ion channels [28, 29]. Population-based modeling provides a high-throughput method to examine trends across diverse cellular phenotypes, while also allowing for mechanistic insights into individual rare events observed in a particular model.

Vanoye et al. recently published a novel dataset of KCNQ1 mutations expressed in Chinese hamster ovary (CHO) cells, characterized using automated planar patch clamp [30]. The functional changes in KCNQ1 for each mutation can be implemented as relative changes in our previously developed iPSC-CM I_{Ks} model. Using a high-throughput population-based computational modeling approach, we analyzed differential mutant impact across diverse whole-cell iPSC-CM phenotypes. We also considered KCNQ1 mutations with known clinical phenotypes and developed a framework to computationally predict the severity of KCNQ1 mutations. Additionally, the matched genetic variant models were incorporated into an adult myocyte in silico to predict mutation impact across a continuum of maturation. In the future, the approach can be expanded to any cardiac target, genetic perturbations, pharmacological interventions, and the complex behavior produced by multi-drug or mutant interactions.

Results

iPSC-CM Wild-Type Model Population

The recently developed Kernik et al. 2019 iPSC-CM population provides an ideal system to analyze cell-to-cell variability in response to genetic mutations within the human physiological system [31]. The iPSC-CM experimental system has been developed for studying genetic perturbations in the true physiological background of a human myocyte [8, 10, 13, 32], and are being increasingly utilized in the study of VUS [18, 19]. Utilizing a computational model of iPSC-CM to study the role of cell-to-cell variability in response to genetic mutations is the best way to ensure an available system for model validation in future studies. The Kernik 2019 population of iPSC-CM models includes experimentally observed variation in kinetic parameters and maximal conductance for five key ionic currents: I_{Kr}, I_{CaL}, I_{Na}, I_{K1}, and I_{f}. The resulting population predicts a wider range of whole-cell action potential morphology, which is shown to be predictive of the experimentally observed range of iPSC-CM action potential morphologies [31]. Utilizing this population of iPSC-CM models with kinetic variation allows for the comparison of cell-to-cell variability in response to genetic mutations, including how mutant kinetics manifest differently depending on kinetics of all other ionic currents. Moreover, investigating the same genetic perturbations in adult cardiac myocyte models and comparing to clinical phenotypes, when known, provides additional evidence to support the use of the iPSC-CM model system for study of genetic perturbation.

Test Set 1: Mutant Model Optimization

We first compiled a set of KCNQ1 mutations that have been identified in terms of both their effect on the I_{Ks} channel and in terms of patient phenotype. This set of mutations is defined as test set 1 (TS1). To analyze the impact of mutations characterized in TS1, experimental data from Vanoye et al. was used to develop a computational model of I_{Ks} that incorporated the kinetic effects of each mutation [30]. For each mutant the I_{Ks} model (Eqs 1–3) were fit to the relative change in G_{Ks}, V_{1/2}, and k between the wild-type (WT) and mutant KCNQ1. Models were optimized to fit measurements by Vanoye et al. recorded using automated patch clamp.
The resulting activation curves ($I_{act}$, $I_{act,\infty}$) and I-V curves for the WT model and each TS1 $I_{Ks}$ mutant model are shown in Fig 1A and 1B, respectively. All of the TS1 mutations have known clinical phenotypes in patients, as detailed in the ClinVar database [33]. Based on ClinVar assessments of TS1 mutations, nine mutants are LQTS pathogenic (Y111C, L114P, P197L, C122Y, E160K, R174C, I204F, A344V, V110I), one mutant is LQTS likely pathogenic (A300T), one mutant is short QT pathogenic (F279I), one mutant is atrial fibrillation pathogenic (S209P), and one mutant is likely benign (V207M). Six of the pathogenic mutants in TS1, which result in insufficient current to measure KCNQ1 current density or $V_{1/2}$ (Vanoye et al, supplemental table S4a [30]), were modeled as complete $I_{Ks}$ block ($G_{Ks} = 0$).

Test Set 1: Predicted Impact of LQT1 on AP Morphology

For each mutant in TS1, we replaced the wild-type $I_{Ks}$ model in our control population of iPSC-CM models with the optimized mutant $I_{Ks}$ model. This resulted in a population of...
iPSC-CM models for each mutation. For a selection of mutations, a subset of APs are shown for the WT and mutant in Fig 2A–2C. It can be seen that some cells within the population are more susceptible to mutations, with several iPSC-CM models showing considerably more prolongation in action potential duration (APD). Total $I_{Ks}$ block and the I204F mutation fall into this category. For each model in each mutant population, AP morphology markers were measured and compared to WT behavior in the same cellular model. The results of this analysis for APD$_{50}$ and APD$_{90}$ are shown in Fig 2D.

The TS1 mutations resulted in a population of 11091–10887 models that were spontaneously beating and fully repolarizing (AP amplitude over 70 mV, resting voltage over 40 mV, and no repolarization abnormalities). Models with repolarization failures did occur and are included in the study as exemplars of pathogenic behavior. The models which developed repolarization failure after implementing each mutation were tracked and reported as a percentage of the total WT population in Table 1. Severe mutants had the highest percentage of models excluded from the population due to repolarization abnormalities.

Previous studies have suggested that utilizing only AP prolongation as an indicator of critical change to AP morphology is an inadequate indication of proarrhythmic phenotypes [34, 35]. To further analyze the predicted impact of KCNQ1 mutations on iPSC-CMs, each cell in each mutant population was also simulated for 40 beats with a physiological noise current. The beat to beat variability of APD$_{90}$ (defined in methods) and triangulation of the APs (APD$_{90}$ - APD$_{30}$) was analyzed following a simulation with applied noise. The bar graph in Fig 2D shows the result of this simulation for each mutation as a percent change compared to the wild-type population, as well as the change in APD$_{90}$ and APD$_{50}$ compared to the wild-type population.

TS1: Development of an LQTS Severity Indication

After comparing iPSC-CM AP morphology and temporal responses to perturbation by KCNQ1 mutations, we developed a framework to categorize the predicted severity of response to each mutant. We considered three criteria in developing a severity test to classify each $I_{Ks}$ mutation. We considered the following criteria for each cell in each mutation population:

1. Increase in the triangulation across 40 beats with physiological noise in the mutant compared to the WT.
2. Increase in average beat-to-beat variation across 40 beats with physiological noise in the mutant compared to the WT.
3. Increase in APD$_{90}$ compared to the WT.

For each mutant population, we considered the percent of cellular models which surpassed a given threshold for the three criteria above. Using this framework with a 4% threshold, we stratified the mutation populations in TS1 to determine the severity of each mutation. The results of this stratification are shown in Fig 3A for TS1. We tested a range of thresholds (4, 5, 8, 10, 15, and 20% change) and saw the same relative stratification of TS1. A comparison of 3 tested thresholds (4%, 8%, and 10%) are shown in Table 1. The table shows the level of clinical of severity (colored in red, yellow, blue and green) based on the ClinVar assertion for each mutation.

In Fig 3B, we show examples of how the criteria and thresholds were applied for example mutant populations. Percent change compared to WT was calculated for each of the three criteria (Fig 3B, left: triangulation and beat-to-beat variation; Fig 3B, right: beat-to-beat variation and APD$_{90}$). All cells in the example mutant population are shown in Fig 3B as individual dots.
Fig 2. Population-based modeling results for test set 1 mutations in iPSC-CMs computational models. (A) For a random subset of the model population (n = 2818), APs are shown for wild-type (grey) and complete $I_{Ks}$ block ($0 \ G_{Ks}$, red). (B) For a random subset of the model population (n = 2826), APs are shown for wild-type (grey) and the I204F mutant (orange). (C) A random subset from the model population (n = 2826) are shown for APs for wild-type (grey) and the V207M mutant (purple). (D) For each mutant cell in TS1, action potential duration 90% ($APD_{90}$), $APD_{50}$, action potential (AP) triangulation, and $APD_{90}$ beat-to-beat variability were computed relative to the wild-type. AP Triangulation ($APD_{90}$-$APD_{30}$) and beat-to-beat variability ($\mid APD_{90,n}-APD_{90,n+1}\mid$, for beat n) were averaged over 40 beats with a physiological noise current. The bar graph shows the mutant population average and standard deviation for each output. APs for mutations highlighted with colored stars are shown in panel A-C.

https://doi.org/10.1371/journal.pcbi.1008109.g002
in the scatter plot. The model cells that met all three criteria above the 4% threshold are highlighted in red for the \( I_{Ks} \) knockout, yellow for the F278I mutation, and green for the V207M mutation. All cells below the threshold criteria are indicated by a grey dot. Comparing the most severe mutant (0 \( G_{Ks} \)) and a low severity mutation (V207M), there is a much-increased spread in cellular outputs (grey and colored) for the severe mutation. This spread is due to the greater change in AP behavior, compared to WT, for each cell in the severe mutant population. Additionally, there are many more highlighted red points for the severe knockout mutation, than green highlighted points for the predicted low severity mutation (V207M).

The six KCNQ1 mutations which had insufficient current density to optimize the \( I_{Ks} \) model (with either \( \leq 0\% \) current density measured experimentally relative to WT, or \( V_{1/2} \) could not be determined), have all been classified as pathogenic LQTS mutations in the ClinVar database. Four mutations (I204F, A344V, V110I, and A300T) classified as LQTS mutations (pathogenic or likely pathogenic) had sufficient experimental data to optimize a mutant \( I_{Ks} \) model. Three of these mutations have all been observed to prolong patient QT interval and are classified as pathogenic LQTS in the ClinVar database (I204F, A344V, V110I). Additionally, A300T has been observed to prolong the QT interval in a clinical study, but it is either a recessive variant or has incomplete penetrance in patients [36]. These 4 mutant populations, as well as the population with 0 \( G_{Ks} \), were predicted to fall into the highest severity stratification in our computational analysis, as shown in Fig 3A.

One mutation included in TS1 is classified as a likely benign variant in the ClinVar database (V207M) and falls in the benign stratification shown in Fig 3A. Finally, there are two mutations which are classified as pathogenic, but for diseases other than LQT (non-LQT pathogenic) as follows: The S209P mutation falls at the lowest severity stratification of our analysis

---

**Table 1. Comparison of ClinVar and Computational Results for TS1.**

| Mutations ordered by size of subpopulation above threshold: | Repolarization Failure (%) |
|---|---|
| | 4% | 8% | 10% |
| Y111C | Y111C | Y111C | 4.7 |
| L114P | L114P | L114P | 4.7 |
| P197L | P197L | P197L | 4.7 |
| G123Y | G123Y | G123Y | 4.7 |
| G179S | G179S | G179S | 4.7 |
| R231C | R231C | R231C | 4.7 |
| L236R | L236R | L236R | 4.7 |
| R174C | R174C | R174C | 4.7 |
| I204F | I204F | I204F | 4.4 |
| A344V | A344V | A344V | 4.3 |
| V110I | V110I | V110I | 4.0 |
| A300T | A300T | A300T | 3.8 |
| F279I | F279I | F279I | 3.5 |
| V207M | V207M | V207M | 3.0 |
| S209P | S209P | S209P | 2.9 |

**LQTS**

| LQTS Likely Pathogenic |
| Non LQTS pathogenic |
| Likely Benign |

*modeled as \( GKs = 0A/F \)

[https://doi.org/10.1371/journal.pcbi.1008109.t001](https://doi.org/10.1371/journal.pcbi.1008109.t001)
and clinically has been associated with atrial fibrillation (AF). In the clinical study, an AF patient with the S209P mutation, the affected patient had no difference in corrected QT (QTc) interval compared to the unaffected family members [37].

Finally, there was one mutation (F279I) in TS1 which was not clearly categorized by our analysis. Interestingly, there is also some lack of clarity in other experimental studies characterizing this mutation. Clinically, F279I has been classified as a short QT syndrome mutation in...
the clinical study by Moreno et al., where they also examined the impact of the mutation on current density in COS7 cells with mutant vs. WT KCNQ1 and observed a gain of current density [38]. This is the opposite effect for F279I mutant KCNQ1 current density observed in the Vanoye et al. data used to optimize our mutant model. The Vanoye et al. data showed a 32% reduction in current density with the F279I mutation. Our framework predict that F279I falls in the range that cannot be clearly classified as pathogenic or benign. This range is highlighted in yellow, between the dashed lines, in Fig 3A.

Based on the 4% threshold and the ClinVar assertions, we determined "cut-offs" for pathogenic and benign mutants, represented as the dashed lines in Fig 3A. The cut-off for pathogenic mutants was set for mutants with more than 4.6% of model cells surpassing the above three criteria (top dashed line, Fig 3A). The cut-off for benign mutants was set for mutants with less than 0.25% of model cells surpassing the above three criteria (lower dashed line, Fig 3A).

**Test Set 2: Comparison of phenotypic variability within mutation populations**

Using the model optimization process shown in Fig 1 for TS1, we optimized the iPSC-CM model $I_{Ks}$ to reflect kinetics and density measured from test set 2 (TS2) mutants. Only mutations with sufficient current density to measure $V_{1/2}$ were included in the analysis. The optimized models of $I_{Ks}$ for each mutation are shown in Fig 4A and 4B. A population of iPSC-CM models was made for each TS2 mutant, as described above for TS1.

Analyzing the cellular models within the TS2 mutant populations reveals profound phenotypic variability resulting from a given mutation. For example, individual cellular responses to two high severity LQTS mutations in TS2 are shown in Fig 4C–4H. The T104I and P197S mutations resulted in the largest mean APD$_{90}$ prolongation (T104I) and the largest increase in AP triangulation (P197S). In comparing populations containing each of these mutants, we observed that some individual iPSC-CM models within the population were more sensitive to T104I (Fig 4C–4E), while a subset of different iPSC-CM models from the same population are profoundly sensitive to P197S (Fig 4F) and exhibit extensive cellular level disruption. Still, other example models are similarly impacted by both mutations (Fig 4G and 4H).

To further analyze mechanisms of differential response to the T104I and P197S mutations, we examined the underlying currents and response to a physiological noise current for the example models shown in Fig 4C and 4F. The ionic current behavior underlying the AP in each of these two cells are shown in Fig 5A and 5B. In example cell 1, the T104I mutation causes longer AP prolongation than P197S (Fig 5A). This difference in AP prolongation is driven primarily by the larger depletion in total $I_{Ks}$ current caused by the T104I mutation. Example cell 1 exhibits similar mutant response when both mutations are modeled by $G_{Ks}$ scaling alone (S1 Fig). Additionally, when the physiological noise current is applied (Fig 5C), P197S maintains a shorter APD than the same cell with the T104I mutation (Fig 5D). However, the opposite trend in AP prolongation is observed in example cell 2. In cell 2, P197S prolongs the AP more than T104I (Fig 5B). The shift in the time course of $I_{Ks}$ during the AP caused by the P197S mutation results in an earlier peak $I_{Ks}$, with near 0pA/pF $I_{Ks}$ at the end of the AP (Fig 5B, orange, Time > 500ms). Example cell #2 model is more sensitive to the depletion in repolarizing current at the end of the AP, in part due to the balance of $I_{Kr}$ and $I_{CaL}$. Thus, the lack of $I_{Ks}$ at the end of the AP in the P197S model results in the more severe AP prolongation for the P197S mutant compared to the T104I mutation. This is most clearly illustrated by the net current ($I_{Kr} + I_{Ks} + I_{CaL}$) during the AP (Fig 5B, bottom panel), with the P197S mutation resulting in less net repolarizing current late in the AP. If the P197S and
Fig 4. Model optimization for test set 2 (TS2) and sample APs comparing selected mutations in TS2. (A) Steady-states activation and (B) IV relationships resulting from optimization of the iPSC-CM $I_{Ks}$ model to fit experimental results for TS2 mutations. (C-H) Wild-Type (black), T104I mutant (blue), and P197S mutant APs are shown for several sample iPSC-CM models within our population. Mutations were selected to demonstrate the greatest average APD$_{90}$ prolongation (T104I) and greatest average increase in triangulation (P197S) in TS2. (C-E) A selection of computational models from the population that showing more impact of the P197S mutation than the T104I mutation. (F) One computational model from the population responds to the T104I mutation with more AP
T104I mutants are modeled as $G_{Ks}$ scaling alone (S1 Fig) the increased P197S prolongation is not observed. Thus, this increased AP prolongation due to P197S is captured due to the mutant model optimization to kinetic parameters ($V_{1/2}$ and $k$). When the physiological noise current is applied, as shown in Fig 5E, the P197S mutation causes some APs to have repolarization abnormalities, as indicated by orange stars. As cell #2 is shown to be sensitive decreased new current late in the AP, the physiological noise current in the P197S mutant model is sufficient to prolong the AP further, and cause EADs.

Test Set 2: Predicted LQTS Severity

Using the populations of iPSC-CMs models we predicted and classified the severity of each mutation in Test Set 2 (TS2) by applying the framework developed for TS1. The results of this analysis are shown in Fig 6A, where the color gradient indicates severity from high (red) to unclear phenotype (yellow) to mild (green). Fig 6B shows a more detailed analysis of the three exemplar mutations (one from each category, severe, unclear and mild LQTS risk) from TS2 where impacts were simulated in a population of iPSC-CM models. The categorization criteria (increase in beat-to-beat variability, APD$_{90}$ prolongation, and increase in triangulation) as shown in Fig 6B.

The predicted severity of each mutation is compared to the Vanoye et al. predicted severity in Table 2. Vanoye et al. used the patch clamp acquired current density data for each KCNQ1 mutation to categorize severity of each mutation (Severe loss of function (LOF) mutations at <25% of WT current density, mild LOF 25–75% WT current density, etc.). Table 2 also shows the percentage of the wild-type model population excluded due to lack of spontaneous beating or repolarization failures for each mutant population. In general, severe mutations caused more repolarization abnormalities in the model population, resulting in a higher percentage.

Notably, GOF mutations (P197L, R109L, and H105L) also caused an increase in the number of models with repolarization failure. Characterization of the GOF mutations are shown in Table 3. GOF function mutation severity was examined using the same 4% threshold for beat-to-beat variation and triangulation criteria, as done for the LOF mutations. The criteria for APD$_{90}$ was defined as the subpopulation of models with a 4% or more shortening of AP duration, compared to WT. However, without available clinical pathogenic characterization of GOF mutations, it is not possible to validate the predictions of pathogenic severity as was done for the comparison of TS1 and TS2 for LQT1.

The increase in repolarization failure occurs in part because the increase in $I_{Ks}$ due to GOF mutations can also cause increase in resting voltage of the AP. GOF mutations P197L, R109L, and H105L cause an average increase in maximum diastolic potential (MDP) of 0.5, 0.13, and 0.08 mV, respectively compared to WT. Severe LOF mutations I227L and V162M cause an average decrease in MDP of -0.13 and -0.16mV, respectively compared to WT. Due to spontaneous beating of all iPSC-CM models in the wild-type population, and the wide variability in our model populations, some model cells are highly sensitive to small changes in resting membrane voltage. An example of repolarization failure caused in part by instability in the resting membrane voltage is shown in Fig 7A. Repolarization failure was defined as failure to reach AP amplitude above 70 mV (see methods). Stabilizing the membrane voltage by simulating the same cell with an increase in $I_{K1}$ can rescue the repolarization failure, as shown in Fig 7B. Increase in $I_{K1}$ has also been shown to stabilize the iPSC-CM AP in several experimental studies [39–41].
Fig 5. Comparison of ionic currents and response to physiological noise current in T104I and P197S mutant models. Sample action potentials from simulated cells with differential response to the T104I and P197S mutations are shown with their underlying currents. (A) Example cell #1 shows more AP prolongation in response to the T104I mutation. The underlying behavior of $I_{Kr}$, $I_{Ks}$, and $I_{CaL}$ is shown during the AP, as well as the sum of these three currents ($I_{Kr} + I_{Ks} + I_{CaL}$). (B) Example cell #2 shows more AP prolongation in response to the P197S mutation. The
underlying behavior of $I_{Kr}$, $I_{Ks}$, and $I_{CaL}$ is shown during the AP, as well as the sum of these three currents ($I_{Kr} + I_{Ks} + I_{CaL}$). (C) Example of the physiological noise current applied to the cellular models to track beat-to-beat variability in response to noise. (D) Response of example cell #1 with physiological noise current. (E) Response of example cell #2 with physiological noise current. The application of low amplitude noise current reveals repolarizations abnormalities in the P197S mutation, as indicated with orange stars.

https://doi.org/10.1371/journal.pcbi.1008109.g005

Fig 6. Prediction of LQTS severity in test set 2 using a population-based approach. The severity sorting framework was applied to test set 2 (TS2). TS2 includes mutations with unknown clinical phenotypes. (A) Predicted stratification of LQTS severity for TS2. Red corresponds to the most severe LQTS mutations, green corresponds to benign mutations for LQTS, and yellow highlights the region of severity which cannot be classified utilizing the framework developed with TS1. (B) Three example mutant populations showing the subpopulation of cells meeting the set criteria. Red highlighted points in the top row represent the 7.28% of cells in the I227L population which surpass the 4% threshold for all three criteria. Yellow highlighted points in the middle row represent the 1.96% of cells in the A150T population which surpass the 4% threshold for all three criteria. Green highlighted points in the bottom row represent the 0.16% of cells in the F127L population which surpass the 4% threshold for all three criteria.

https://doi.org/10.1371/journal.pcbi.1008109.g006
Our model predictions are in good agreement with the reported data in the literature for the mutations in TS2 [42–49]. Interestingly, R195Q and Q107H were classified as mild LQTS mutations in the recent study by Vanoye et al, whereas our method (which utilized the Vanoye data) rather suggested a severe pathogenic phenotype, consistent with other in silico approaches [42, 43]. Additionally, while Vanoye et al. classified the T153M mutation as a mild loss of function, the cellular level iPSC-CM computational model method predicts T153M to be benign. In the simulated T153M mutant population, 0.14% model cells are above all three

### Table 2. Comparison of Vanoye et al. and Computational Results for TS2.

| Vanoye et al. Analysis | Computational Modeling Results |
|------------------------|--------------------------------|
| Mutation               | Current Density (% expt.) | Mutation (Colored by Vanoye Classification) | Models meeting criteria (%) | Modeling Severity Prediction | Repolarization Failure (%) |
| P197S                  | 0.17                        | P197S                                    | 9.94                        | Severe LQTS                 | 6.1                        |
| R192C                  | 0.21                        | I227L                                    | 7.22                        | Severe LQTS                 | 4.4                        |
| T104I                  | 0.22                        | V162M                                    | 7.05                        | Severe LQTS                 | 4.0                        |
| I227L                  | 0.22                        | T104I                                    | 6.83                        | Severe LQTS                 | 4.4                        |
| C136F                  | 0.23                        | R192C                                    | 4.86                        | Severe LQTS                 | 4.5                        |
| V162M                  | 0.24                        | V215G                                    | 4.73                        | Severe LQTS                 | 3.9                        |
| V215G                  | 0.33                        | Q167H                                    | 4.55                        |                                | 3.8                        |
| Q107H                  | 0.36                        | R195Q                                    | 4.55                        |                                | 3.9                        |
| V241I                  | 0.44                        | E146K                                    | 4.44                        |                                | 3.8                        |
| K218E                  | 0.46                        | V241I                                    | 3.70                        |                                | 3.0                        |
| R195Q                  | 0.49                        | C136F                                    | 3.51                        |                                | 4.4                        |
| T144A                  | 0.5                         | K218E                                    | 3.21                        |                                | 3.7                        |
| A150T                  | 0.58                        | A150T                                    | 1.93                        |                                | 3.6                        |
| M210I                  | 0.63                        | L187P                                    | 1.95                        |                                | 3.5                        |
| E146K                  | 0.65                        | T169M                                    | 1.06                        |                                | 3.4                        |
| T169M                  | 0.65                        | T144A                                    | 1.00                        |                                | 3.4                        |
| V133I                  | 0.67                        | V129I                                    | 0.74                        |                                | 3.3                        |
| T153M                  | 0.67                        | M210I                                    | 0.72                        |                                | 3.4                        |
| L187P                  | 0.68                        | A150G                                    | 0.62                        |                                | 4.1                        |
| F127L                  | 0.8                         | V133I                                    | 0.36                        |                                | 3.6                        |
| V129I                  | 0.83                        | P197L                                    | 0.23                        | Benign LQTS                  | 12.3                       |
| A150G                  | 0.93                        | R109L                                    | 0.23                        | Benign LQTS                  | 11.1                       |
| H105L                  | 1.31                        | T153M                                    | 0.14                        | Benign LQTS                  | 3.0                        |
| P197L                  | 1.47                        | F127L                                    | 0.16                        | Benign LQTS                  | 5.3                        |
| R109L                  | 2.23                        | H105L                                    | 0.09                        | Benign LQTS                  | 6.3                        |

Severe LOF, Mild LOF, Near Normal, Normal, Severe GOF

Our model predictions are in good agreement with the reported data in the literature for the mutations in TS2 [42–49]. Interestingly, R195Q and Q107H were classified as mild LQTS mutations in the recent study by Vanoye et al, whereas our method (which utilized the Vanoye data) rather suggested a severe pathogenic phenotype, consistent with other in silico approaches [42, 43]. Additionally, while Vanoye et al. classified the T153M mutation as a mild loss of function, the cellular level iPSC-CM computational model method predicts T153M to be benign. In the simulated T153M mutant population, 0.14% model cells are above all three

### Table 3. Computational Results for GOF mutations.

| Mutation | Models meeting SQT criteria (%) | Repolarization Failure (%) |
|----------|---------------------------------|-----------------------------|
| P197L    | 9.56                            | 12.3                        |
| R109L    | 2.37                            | 11.1                        |
| H105L    | 0.01                            | 6.3                         |

https://doi.org/10.1371/journal.pcbi.1008109.t003
prediction criteria, and similarly our model predicts 0.09% model cells above all criteria for V207M mutant, a TS1 clinically benign mutant. This is consistent with the likely benign ratio-
nale discussed in the ClinVar entry for the T153M mutation [44]. Similarly, our approach pre-
dicted the C136F mutation to be less severe than the Vanoye et al. classification. Based on the
distribution of the severity of mutations in TS1, C136F falls into the range of risk outputs
which are not predicted by our framework as conclusively pathogenic or benign. This may be
due to the fact that mutations within this range have incomplete penetrance or require addi-
tional environmental, pharmacological, or genetic perturbations to cause a pathogenic pheno-
type. This is consistent with the literature for five other mutations in TS2 which fall within this
range (C136F [45], A150T [46], T144A [47], L187P [48], and K218E [49]).

It should be noted that the expression of these mutant channels is expected to vary from
cell-to-cell and patient-to-patient. Furthermore, TS1 and TS2 variants were characterized by
Vanoye et al. in a homozygous state, as opposed to being co-expressed with the WT channel in
vitro. Within the homozygous state there is some experimentally observed variation param-
eters, including current density. This variability was not included in TS1 and TS2. S2 Fig (S2
Fig) shows example APs resulting from simulating variability in mutant maximal conductance.
Example Cell 1 from Fig 5, is simulated using the base mutant model from TS2, compared to
mutant models with variable current density within 2-times the experimentally observed stan-
dard error. While variation in the maximal conductance will cause some variation in disease
phenotype, this variation is relatively small compared to the range of WT phenotypes included
in the model population. To study the heterozygous state, test set mutants were expressed with
the WT allele and characterized in Vanoye et al., as a model system for determining autosomal
dominant traits. Based on the homozygous variant data, as discussed previously for TS1 and
TS2, the selected mutants were all characterized as pathogenic in Vanoye et al. and our model
system. Additionally, we have simulated model populations with I_{Ks} optimized to the

Fig 7. Example of repolarization irregularity in gain of function (GOF) mutant. (A) Sample action potential
showing repolarization irregularity in P197L mutant, a GOF mutation, compared to wild-type. (B) Stabilization resting
potential by increased in G_{K1}. GOF mutant causes expected shortening of AP duration, and increase in G_{K1} prevents
repolarization irregularity.

https://doi.org/10.1371/journal.pcbi.1008109.g007
experimental data collected from the WT/variant heteromultimeric channels, as shown in S3 Fig (S3 Fig.). Consistent with the Vanoye et al. results, the mutant phenotype was consistently less severe when the model is fit to the WT/variant data, rather than the variant/variant data as shown in Figs 4 & 6. However, only one mutant characterized in the WT/variant system has a known clinical pathogenic phenotype (G314S), and the majority of variants characterized have a similar impact on the model population, compared to the known pathogenic variant (S1 Fig.). Three mutants (I227L, V162M, G179A) seem to have a less severe whole-cell impact in the heterozygous system, consistent with the conclusions from Vanoye et al. As only one mutant with known clinical phenotype (G314S, pathogenic) was characterized in this heterozygous system, it is not presently possible compare a clinically know and unknown set of mutants, as was done for TS1 and TS2 in this study.

Validation of KCNQ1 mutation effects in adult ventricular model

In this study, we have examined the effects of a variety of KCNQ1 mutations in two test sets, TS1 and TS2 by predicted the impact of individual mutants in iPSC-CMs models. However, an important drawback of the iPSC-CM approach as both an experimental and simulated model system is that there is no clear way to determine how the model outputs will relate to adult phenotypic manifestation of genetic variants. For this reason, we next developed an adaptation for the computational models of KCNQ1 mutants that we tested in the iPSC-CMs models to allow for prediction of their effects on the adult cardiac ventricular myocyte (model formulation is described in the methods). Fig 8A shows the predicted relationship between APD$_{90}$ and APD triangulation for each mutation in the Mann et al. optimization of the O’Hara-Rudy (ORd) adult ventricular cell model[50, 51]. The Mann et al. global optimization of the ORd model results in increased model APD prolongation is response to pathogenic LQT mutations, as compared to the original ORd Model. Interestingly, the mutations which were predicted to result in the most severe phenotypes in the iPSC-CM modeling approach also show the largest increase in AP duration and triangulation in the adult ventricular cell model. The mutation effects on the AP are shown for example mutations in Fig 8B–8D, and the trend across all 33 mutations analyzed is in consistent agreement with the predictions from the iPSC-CM population.

Discussion

Induced pluripotent stem-cell derived cardiomyocytes (iPSC-CMs) are a promising reagent utilized in a variety of methods to reveal human cardiac behavior in a physiological context and expand understanding of cardiac disease and drug response. Currently, the use of iPSC-CMs is limited by three main factors: (1) difficulty in representing phenotypic variability experimentally, (2) low throughput electrophysiological measurements, and (3) the immature phenotype may not accurately represent adult cardiac behavior in all conditions. In this study we developed a computational modeling and simulation approach to address all three limitations and serve as a complementary approach to in vitro studies.

We utilized experimental data describing KCNQ1 kinetics and current density in CHO cells to develop computer models of normal and mutant cardiac slowly activating delayed rectifier potassium current $I_{Ks}$. Through development of these computational models, the impact of each mutation can be observed within the cellular context, in order to reveal the mutation effect on whole-cell behavior. The wild-type and mutant current models were incorporated into populations of iPSC-CM computer models that we recently developed and described [31]. By making predictions across a population of computer models representing the observed range of cell-to-cell variation in iPSC-CM electrophysiology, we were able to predict the
Fig 8. The predicted impact of \( \text{I}_{\text{Ks}} \) mutations from test set 1 and test set 2 in the O’Hara–Rudy computational model of the adult ventricular cardiomyocyte. (A) Each mutated \( \text{I}_{\text{Ks}} \) model was adapted for the adult ventricular cardiomyocyte model by incorporating relative changes in gating. APD\(_{90}\) and triangulation of the Mann et al. optimization of the O’Hara-Rudy computational model of the adult ventricular cardiomyocyte with each mutant \( \text{I}_{\text{Ks}} \) model is shown for three pacing rates with basic cycle lengths (BCL) or 750 ms, 1000 ms, and 1250 ms. Starred mutations (*) are from test set #1 (TS1), remaining mutations are from test set #2 (TS2). The color of each mutation is determined by the designated classifications in the iPSC-CM model populations, as shown for TS1 (Fig 3A) and TS2 (Fig 4A). (B) The adult ventricular cellular model AP for wild-type (grey, dashed) and I204F mutant (red) at cycle length (CL) 750 ms. (C) The adult ventricular cellular model AP for wild-type (grey, dashed) and A150T mutant (yellow) at CL = 750 ms. (D) The adult ventricular cellular model AP for wild-type (grey, dashed) and F127L mutant (green) at CL = 750ms.

https://doi.org/10.1371/journal.pcbi.1008109.g008
impact of mutations on a computer-based representation of diverse genetic backgrounds and thus observe rare events. The framework allowed for an efficient mode of analysis for many the range of emergent behaviors arising from mutations. The range of observed behaviors indicate that population modeling has some advantages over previously developed approaches which focus on average cellular level impacts of mutations [52].

Experimental data describing functional impacts of mutations with known clinical phenotypes were labeled test set 1 (TS1). Data from this group of mutations was used to develop a computational framework for assessing LQTS severity. By applying random parameter variation from within experimentally reported data ranges to develop a population of iPSC-CM models [31], we predicted a wide range of phenotypic responses to each mutation.

We stratified the TS1 iPSC-CM mutant model populations by severity through tracking the fraction of model cells that exhibited diseased phenotypes. We tracked multiple parameters including AP prolongation, AP triangulation, and beat-to-beat variability. The model correctly separated mutations that were observed clinically to be pathogenic or benign. Using these results and the clinically observed outcomes for the TS1 mutants, we determined pathogenic “cut-offs” and then applied them to predict the severity of mutations in test set 2 (TS2). We also assessed the impact of all mutants in the adult setting by simulating their effects in the O’Hara-Rudy adult cardiac ventricular myocyte model. It was notable that the predicted impacts of individual mutations in the immature iPSC-CM mutant model populations were consistent with the predictions that emerged in the adult model cell populations, suggesting that the iPSC-CM model system may indeed provide valuable and relevant genotype phenotype information.

Comparing the predictions from experimental data in Vanoye et al., where the authors utilized ionic current as the severity indicator and our computational model framework that relies on whole-cell membrane potential predictions (Table 2), reveals some differences arising from the two approaches. While Vanoye et al. classified the T153M mutation as a mild loss of function, the cellular level iPSC-CM computational model method predicts T153M to be benign. It should be noted that the Stanford Center of Inherited Cardiovascular disease submission in ClinVar for this disease categorizes the mutation as likely benign due to its common minor allele frequency (MAF) in the general population, but a lack of confirmed LQTS diagnosis [44]. The consistent prediction of the computer model with the ClinVar database may indicate the importance of a population-based approach where emergent cellular level phenotype predictions suggest that most genetic backgrounds mask the impact of the mutation.

The Q107H and R195Q mutations have previously been studied in mechanistic studies, which predicted the mutations to be likely pathogenic in alignment with our prediction of these mutants near the pathogenic range. For Q107H, a structural modeling study concluded that the mutation would destabilize folding, suggesting a disease mechanism [42]. Additionally, the KCNQ1 mutation R195Q was evaluated by Clemens et al. and showed that 6 of 8 in silico phenotyping algorithms utilizing genetic sequence information classified the R195Q mutation as pathogenic [43]. The iPSC-CM model population, by accounting for the impact of other ionic currents, compensatory behavior in the whole-cell, and variability in response between patients and cells, allows for a more specific interpretation of risk (and associated score) for mutations between the severe and benign classifications. The predictions suggest that both Q107H and R195Q fall near the border of severe and mild LQT severity scores (Fig 6) and may be pathogenic for a fraction of patients dependent on the underlying genotype. The cellular level predictions seemed to even account for incomplete penetrance in a population, which is consistent with recessive A300T mutations from TS1 [36], and resulted in a similar LQTS severity score (A300T = 4.8, Q107H = 4.6, R195Q = 4.6).
There are additional instances where the cellular level iPSC-CM computational modeling and simulation approach did not agree with the Vanoye et al. classification. An example is the C136F mutation. Based on the distribution of the severity of mutations in TS1, C136F falls into the range of risk outputs which are not predicted by our framework as conclusively pathogenic or benign. The range of mild mutations (yellow, Table 2), has an interesting clinical prevalence in the literature. Three mutations (C136F [45], A150T [46], and T144A [47]) have each respectively been identified in a single patient diagnosed with LQTS using genotyping of LQTS patients. However, existence of a mutation in a single patient is insufficient information to conclude pathogenicity. Although a single mutation in an LQTS-susceptible gene in a patient exhibiting prolonged QTc may indicate causality, other interpretations include; (1) the patient has other contributing factors, including genetics, making them especially sensitive to a mutation, or (2) the patient has a completely separate genetic mutation causing the disease phenotype.

The alternative gene cause is exemplified in the case of another mutation in TS2: V133I. The V133I mutation, which our method predicts to be near benign, was identified in a patient case of sudden cardiac death (SCD). However, it was subsequently discovered that the KCNQ1 V133I was unlikely to be the cause of the SCD, and it was instead caused by a separate pathogenic desmin contractile protein mutation [53]. This serves as an example where low-throughput clinical observation in a single patient is insufficient to predict pathogenicity. However, in combination with the methods presented in this study, we can suggest that a mutation is sufficient to cause disease or suggest the likelihood of an alternative explanation for a given phenotype.

Two other TS2 mutations (L187P and K218E) which fall within the predicted mild phenotype range (yellow, table 2 and Fig 6A) suggest that these mutations may require additional contributing factors to cause pathogenicity. Zhang et al. studied the L187P mutation in a family with some members showing QTc prolongation, but 58% of family members possessing the L187P mutation had normal to borderline prolonged QTc [48]. This suggests a mild clinical penetrance of the L187P mutation, which resulted in a VUS classification in ClinVar. The incomplete penetrance of the L187P mutations may be due to additional gene modifiers, environmental factors, or other patient-to-patient variations which protect against or promote the LQT phenotype in some family members. Prior studies have shown that LQT mutations often show incomplete penetrance [54, 55], and additional gene modifiers can amplify potentially pathogenic mutants [56–59].

Another example of mutations that depend on additional perturbations to cause LQTS are acquired, or drug-induced, Long QT (aLQTS) mutations, where mutations are only associated with disease phenotypes in the presence of drugs. In TS2, the K218E mutant was associated with the development of arrhythmias in the presence of dofetilide [49]. Genetic mutations linked to drug-induced QT prolongation have been observed for many LQT related genes [60–64], and the mechanisms of these aLQTS mutations has been explored in silico [65, 66]. The iPSC-CM mutant model framework can be readily expanded to include genetic and drug impacts in future studies.

The evidence shows mutations such as L187P and K218E, which are classified as mild in the iPSC-CM mutant model predictions, can cause LQTS with concomitant genetic predisposition or additional perturbations. It is possible that other mutations with a similar predicted outcome (V241I, C136F, A150T, T144A, and T169M) require additional perturbations to exhibit pathogenic phenotypes. Due to the broad parameter space we sampled in the iPSC-CM computational model population, we did identify some instances that are particularly susceptible to LQT and may be representative of naturally occurring genotypes which possess predisposition to LQT [67]. Patients with multiple mutations in LQTS genes have increased risk of
life-threatening cardiac events, so it is also possible that a single mutation is safe for most patients but in combination with additional mutations becomes life threatening [68].

There are several limitations of this study which may impact the severity of the characterized mutations. The experimental data used to characterize these $I_Ks$ models was conducted in a homozygous system, despite that LQTS is often inherited in an autosomal dominant manner. As experimental characterization of the complete TS1 and TS2 mutations were not been conducted in the heterozygous state (co-expression of mutant and WT KCNQ1), It is also not possible to know if in humans, the heterozygous state results in 50% transmission of mutant and WT alleles, as multiple other states are possible including dominant negative effects and mosaicism. Vanoye et al. did include an analysis of the most severe homeric channel phenotypes in the WT/ mutant heteromultimeric channels, as modeled in Supplemental S3 Fig (S3 Fig.). Furthermore, even in the homozygous state, there can be variability in the maximal current density, as observed in Vanoye et al. and simulated in S2 Fig (S2 Fig.). Many other factors which may also impact the severity of these mutations, including activation of the sympathetic nervous system. Since sympathetic nervous systems has been shown to increase the severity of these mutations, we would anticipate an increase in severity of mutation. However, as we have only made predictions for TS2 relative to TS2, and both test sets were conducted experimentally under the same conditions. In the future, this computational modeling approach could be expanded to include contributions from these pathways, as has been done in other models of cardiomyocytes[69, 70].

Finally, the prediction of the mutation effects in the adult model system represents a first step toward utilizing phenotypic variability in iPSC-CM modeling to make predictions in the adult system. In the near future, deep learning based "translation" approaches to convert iPSC-CM modeling results to adult cardiomyocyte response can be used to expand the methodology presented in this study. The analysis of LQT1 mutants in the adult model serves a validation of the utility of modeling mutations in the iPSC-CM system, while utilizing the phenotypic variability incorporated in the iPSC-CM model system to examine cell-to-cell variability in response to mutations. An ideal system would model iPSC-CM mutations, use the iPSC-CM model system to extrapolate population-based iPSC-CM response to mutations, and translate the iPSC-CM population to an adult patient-population of models. Utilizing the currently available experimental data and iPSC-CM modeling approaches, this study is a first step toward applying iPSC-CM phenotypic variability to understand variation in disease expression.

The modeling approach applied in this study serves as an in silico complement to existing methods to linking genotype to phenotype. We have utilized experimental and clinical data to develop $I_Ks$ mutant models and determine the range of pathogenic and benign behaviors in the model framework. Together this allowed for the simulation of the impact of LQT1 mutations and VUS on diverse phenotypes and predict the severity of mutations without known clinical outcomes. Finally, by using a computational model to simulate the impact of mutations from both the immature iPSC-CM models to the O’Hara-Rudy adult ventricular cardiac myocyte model, we have demonstrated the impact of mutations across the continuum of aging. In the future, the approach can be expanded to examine additional cardiac mutations or pharmacological interventions. Furthermore, a population-based approach will be critical in identifying patient phenotypes that are particularly susceptible to unintended drug effects and developing multi-drug treatments to mitigate those effects.
Methods
IKs Model Optimization
As described in our previous study of an iPSC-CM model [31], I_{Ks} gating was modeled using single-exponential rate functions such that:

\[ I_{Ks} = G_{Ks} \cdot x_{act}^2 \cdot (V_m - E_K) \]  
Eq (1)

\[ x_{act,\infty} = \frac{1}{1 + x_3 \cdot e^{V/V_1/2}} = \frac{1}{1 + x_6 \cdot e^{V/V_1/2}} \]  
Eq (2)

\[ \tau_{x,act} = \frac{1}{x_1 \cdot e^{V/V_2} + x_5 \cdot e^{V/V_1/2}} + x_5 \]  
Eq (3)

Model parameters x_1-5 and G_{Ks} were optimized for each mutation simulated. I_{Ks} mutants were optimized based on the shift in \( V_{1/2} \) and k (slope) of steady-state activation (\( x_{act,\infty} \)), and the current density (G_{Ks}). Experimental data reporting the change in each parameter between cells expressing the wild-type (WT) and mutated KCNQ1 channel, as reported in Vanoye et al., were used for model optimization. For example, for the I204F mutation Vanoye et al. reported a 14.8 mV positive shift in \( V_{1/2} \) between the control and mutant experimentally measured activation curves. Thus, our I204F I_{Ks} model was fit to a 14.8 mV shift in \( V_{1/2} \) from our previously published WT iPSC-CM I_{Ks} model. Similarly, the changes in k and current density compared to WT, as measured experimentally in Vanoye et al., was used to further constrain the steady-state activation curve and determine G_{Ks}, respectively.

Defining Test Sets of Mutations
All mutations modeled were characterized experimentally in Vanoye et al. [30]. The experimental study included a training set of mutations and a test set of mutations, which served as the basis of the two sets of mutations modeled in this study: test set 1 (TS1) and test set 2 (TS2). TS1 includes the 15/30 mutations in the Vanoye et al. training set with known clinical phenotypes in the ClinVar database [33]. Of these mutations 8/15 mutations were modeled as complete I_{Ks} block (G_{Ks} = 0), due to insufficient current to characterize these mutations experimentally.

TS2 includes all mutations in the Vanoye et al. test set (25/48 mutants) which had sufficient experimental data to optimize the I_{Ks} model (\( V_{1/2}, k, \) and current density). The remaining 23 mutations included in the Vanoye et al. test set had insufficient current to characterize a model, and would be modeled as complete I_{Ks} block, as done in TS1. For clarity we did not include Vanoye et al. test set mutations which resulted in complete I_{Ks} block (G_{Ks} = 0), due to insufficient current to characterize these mutations experimentally.

Implementation of Model Populations
To analyze the impact of individual mutants on whole cell electrical behavior in the simulated iPSC-CM, we incorporated each I_{Ks} mutation in a population of iPSC-CM models developed previously in Kernik et al. [31]. We utilized the model population which included variation in five major ionic currents (I_{Na}, I_{CaL}, I_{Ks}, I_{K1}, and I_{f}). In Kernik et al. (2019), variation was modeled by fitting the model to multiple experimental kinetic datasets to predict phenotypic variability in the electrical response of the whole-cell model. This model population can serve to
represent phenotypic variability in response to LQT mutations. The published control model population did not include variation in the $I_{Ks}$ model parameters. Here, we applied perturbations to the $I_{Ks}$ parameters to replicate the effect of each mutation and then tested the impact of the $I_{Ks}$ mutant in the population. For example, for the I204F mutant, every cell in the simulated iPSC-CM population contains the six parameters that were optimized to the experimental data for I204F.

The simulated iPSC-CM population comprised 11422 model cells described in Kernik et al. [31]. All “wild-type” cells were deemed to have met the inclusion criteria if they were spontaneously beating and fully repolarizing (AP amplitude over 70 mV, resting voltage below -40mV, no alternans, and no repolarization abnormalities). Each $I_{Ks}$ mutation was then incorporated into each cell in the population and the simulation was allowed to run until steady-state was achieved. Steady state was defined by a <1% change in minimum ion concentrations between the first and last beat of a 50s simulation run. Steady-state conditions were the same as defined for the control iPSC-CM population in Kernik et al. After reaching steady-state (ranging from 60-600s), a 20s simulation was run starting at steady-state initial conditions, and AP morphology markers were analyzed. Additional AP properties were then analyzed during simulation with physiological noise, as described in the next section. Severity indication analysis was conducted using the model subpopulation that retained normal repolarization with the mutation based on the inclusion criteria: AP amplitude over 70 mV, no alternans, and no repolarization abnormalities. This was done in part to account for the impact of the elevated resting potential within the model population, as observed in iPSC-CMs.

Instability of the resting voltage and spontaneous beating due to a lack of $I_{K1}$ is a critical consideration when utilizing iPSC-CMs as a model cell-type [39]. Due to the lack of $I_{K1}$, and resulting elevated resting potential in some iPSC-CMs, a fraction of LQT1 mutant iPSC-CM model cells do not produce a complete AP after loss of repolarizing current in LQT. These “incomplete” APs were identified as APs with amplitude <70mV. Similar abnormalities are seen experimentally, where injected $I_{K1}$ was required to observe drug-induced APD prolongation in some iPSC-CMs [41, 71], or APD prolonging drugs were observed to stop spontaneous beating in iPSC-CMs [72]. However, cessation of spontaneous beating is not inherently a proarrhythmic quality of cardiac cells, as normal adult ventricular cardiomyocytes do not beat spontaneously [73]. To remain consistent between our previous analysis of the wild-type iPSC-CM model population and to allow comparison of mutant and wild-type outputs in each cellular model, models with repolarization abnormalities were not included in our severity analysis. However, models which developed repolarization failures in the mutant population were tracked, and the percentage of models with repolarization failures are listed in Tables 1 and 2.

**Physiological Noise Current**

Each model cell was subject to a physiological noise current application, with noise applied after steady state was reached. Each cell was simulated for 40 beats with physiological noise current applied, and the final beat was saved for analysis. Simulations for test set 1 were undertaken for variable duration (20, 30, and 40 beats with physiological noise). The duration of the simulation did not impact the results. The noise current ($I_{\text{Noise}}$) was formulated as additive Gaussian white noise of amplitude 0.045 pA/pF. This amplitude was determined by matching the amplitude of $I_{\text{Noise}}$ based on prior calculations of physiological noise current in cardiac myocytes [74]. For each simulation with $I_{\text{Noise}}$, beat-to-beat variability and triangulation were analyzed. Beat-to-beat variability was defined as the absolute value of $\text{APD}_{90,n} - \text{APD}_{90,n+1}$ averaged for beat $n = 1$ to beat $n = 39$. Triangulation of each beat is calculated as $\text{APD}_{90} - \text{APD}_{30}$ for each action potential.
Adult Ventricular Models

The O’Hara-Rudy (ORd) ventricular model, as optimized by Mann et al. for LQT, was used to predict adult response to mutants, referred to as the Mann-ORd model [50, 51]. From the original ORd model, the Mann-ORd model used in this study includes scaling factors for $G_{Ks}$, $G_{CaL}$, the sodium-calcium exchanger ($I_{NCX}$), and the sodium-potassium pump ($I_{NaK}$), optimized in Mann et al. to recapitulate the LQT phenotype in adult ventricular cardiomyocytes. $G_{Ks}$ from the iPSC-CM WT model was scaled by a factor of 3.5 to adapt the iPSC-CM $I_{Ks}$ model to the Mann-ORd whole-cell model. This scaling factor was determined by replacing the ORd $I_{Ks}$ model with the iPSC-CM $I_{Ks}$ WT model, and scaling $G_{Ks}$ to maintain $APD_{90}$ from the baseline Mann-ORd model ($APD_{90} = 248$ ms at BCL = 750 ms). For each mutant $I_{Ks}$ model, the same $G_{Ks}$ scaling factor was used to convert the iPSC-CM $I_{Ks}$ mutant model to the adult mutant $I_{Ks}$ model. All other parameters from the iPSC-CM $I_{Ks}$ mutant models were retained in the adapted adult mutant models.

Supporting information

S1 Fig. Comparison of ionic currents in T104I and P197S mutants modeled with $G_{Ks}$ scaling only. Sample action potentials from simulated cells with T104I and P197S mutations modeled by only scaling $G_{Ks}$. $G_{Ks}$ scaling factors were the WT-normalized Vanoye et al. current density measurements (Table 2). Example cell WT models are the same as in Fig 5 (A) Example cell #1 shows more AP prolongation in response to the T104I mutation, similar to mutant response shown in Fig 5. The underlying behavior of $I_{Kr}$, $I_{Ks}$, and $I_{Cal}$ is shown during the AP, as well as the sum of these three currents ($I_{Kr} + I_{Ks} + I_{Cal}$). (B) Example cell #2 shows nearly identical prolongation in response to T104I and P197S mutations, unlike the model with mutant $I_{Ks}$ kinetics. With mutant kinetics, as shown in Fig 5, there was more prolongation with the P197S mutant. The underlying behavior of $I_{Kr}$, $I_{Ks}$, and $I_{Cal}$ is shown during the AP, as well as the sum of these three currents ($I_{Kr} + I_{Ks} + I_{Cal}$).

S2 Fig. Simulated APs for WT example cell 1 (as shown in Fig 5) compared with the base mutant model (as simulated for TS2, shown in Fig 5), and mutant models with ±4% and ±8% change in $G_{Ks}$ scaling factor. $G_{Ks}$ is scaled to 16%, 20%, 24%, 28% and 32% of WT $G_{Ks}$ for the -8%, -4%, base mutant, +4%, and +8% simulated traces, respectively.

S3 Fig. The severity sorting framework was applied to KCNQ1 mutants characterized in the WT/variant heteromultimeric channel. The G314S mutant is the only included mutant characterized as clinically pathogenic, and is highlighted in red. (A) Predicted stratification of LQTS severity based on percentage of population meeting all three criteria for each mutant. (B) Table summarizing simulated results for each mutant. Models meeting criteria is the same as shown in panel A. Repolarization failure is determined as done for TS1 and TS2 in Tables 1–3.

Author Contributions

Conceptualization: Divya C. Kernik, Pei-Chi Yang, Junko Kurokawa, Joseph C. Wu, Colleen E. Clancy.

Formal analysis: Divya C. Kernik, Pei-Chi Yang.
Funding acquisition: Junko Kurokawa, Joseph C. Wu, Colleen E. Clancy.
Investigation: Divya C. Kernik, Pei-Chi Yang.
Methodology: Divya C. Kernik, Pei-Chi Yang, Colleen E. Clancy.
Validation: Colleen E. Clancy.
Visualization: Divya C. Kernik.
Writing – original draft: Divya C. Kernik, Colleen E. Clancy.
Writing – review & editing: Divya C. Kernik, Pei-Chi Yang, Junko Kurokawa, Joseph C. Wu, Colleen E. Clancy.

References
1. Tester DJ, Ackerman MJ. Genetics of long QT syndrome. Methodist Debakey Cardiovasc J. 2014; 10(1):29–33. Epub 2014/06/17. https://doi.org/10.14797/mdcj-10-1-29 PMID: 24932360; PubMed Central PMCID: PMC4051331.
2. Westenskow P, Splawski I, Timothy KW, Keating MT, Sanguinetti MC. Compound mutations: a common cause of severe long-QT syndrome. Circulation. 2004; 109(15):1834–41. Epub 2004/03/31. https://doi.org/10.1161/01.CIR.0000125524.34234.13 PMID: 15051636.
3. Napolitano C, Priori SG, Schwartz PJ, Bloise R, Ronchetti E, Nastoli J, et al. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA. 2005; 294(23):2975–80. Epub 2006/01/18. https://doi.org/10.1001/jama.294.23.2975 PMID: 16414944.
4. Amin AS, Giudicesi JR, Tijssen AJ, Spanjaart AM, Reckman YJ, Klemens CA, et al. Variants in the 3' untranslated region of the KCNQ1-encoded Kv7.1 potassium channel modify disease severity in patients with type 1 long QT syndrome in an allele-specific manner. Eur Heart J. 2012; 33(6):714–23. Epub 2011/12/27. https://doi.org/10.1002/ehj3.1619999944; PubMed Central PMCID: PMC3303714.
5. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med. 1992; 327(12):846–52. Epub 1992/09/17. https://doi.org/10.1056/NEJM199209173271204 PMID: 1508244.
6. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001; 103(1):89–95. Epub 2001/01/04. https://doi.org/10.1161/01.cir.103.1.89 PMID: 11136691.
7. Goldenberg I, Moss AJ. Long QT syndrome. J Am Coll Cardiol. 2008; 51(24):2291–300. Epub 2008/06/14. https://doi.org/10.1016/j.jacc.2008.02.068 PMID: 18549912.
8. Matsa E, Burridge PW, Yu KH, Ahrens JH, Termglinchan V, Wu H, et al. Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro. Cell Stem Cell. 2016; 19(3):311–25. https://doi.org/10.1016/j.stem.2016.07.006 PMID: 27545504; PubMed Central PMCID: PMC5087997.
9. Liang P, Lan F, Lee AS, Gong T, Sanchez-Freire V, Wang Y, et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation. 2013; 127(16):1677–91. https://doi.org/10.1161/CIRCULATIONAHA.113.011883 PMID: 23519760; PubMed Central PMCID: PMC3870148.
10. Burridge PW, Li YF, Matsa E, Wu H, Ong SG, Sharma A, et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med. 2016; 22(5):547–56. https://doi.org/10.1038/nm.4087 PMID: 27089514; PubMed Central PMCID: PMC5086256.
11. Ma D, Wei H, Lu J, Huang D, Liu Z, Loh LJ, et al. Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes. Stem Cell Res Ther. 2015; 6:39. https://doi.org/10.1186/s13287-015-0027-z PMID: 25889101; PubMed Central PMCID: PMC4396080.
12. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Fluegel L, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med. 2010; 363(15):1397–409. https://doi.org/10.1056/NEJMoa0908679 PMID: 20660394.
13. Liang P, Sallam K, Wu H, Li Y, Itzhaki I, Garg P, et al. Patient-Specific and Genome-Edited Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Brugada Syndrome. J Am Coll Cardiol. 2016; 68(19):2086–96. https://doi.org/10.1016/j.jacc.2016.07.779 PMID: 27810048.

14. Novak A, Barad L, Lorber A, Gherghiceanu M, Reiter I, Eisen B, et al. Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations. J Cell Mol Med. 2015; 19(8):2006–18. https://doi.org/10.1111/jcm.12581 PMID: 26153920; PubMed Central PMID: PMC4549051.

15. Kodo K, Ong SG, Jahanbani F, Termglitchen V, Hiroko K, Inanloo Rahalloo K, et al. iPSC-derived cardiomyocytes reveal abnormal TGF-beta signalling in left ventricular non-compaction cardiomyopathy. Nat Cell Biol. 2016; 18(10):1031–42. Epub 2016/09/20. https://doi.org/10.1038/rcmb.2016.276 PMID: 27642787; PubMed Central PMID: PMC5042877.

16. Yoshida Y, Yamanaka S. Induced Pluripotent Stem Cells 10 Years Later: For Cardiac Applications. Circ Res. 2017; 120(12):1958–68. Epub 2017/06/10. https://doi.org/10.1161/CIRCRESAHA.117.311080 PMID: 28596174.

17. Yokoo N, Baba S, Kaichi S, Niwa A, Mima T, Doi H, et al. The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. Biochem Biophys Res Commun. 2009; 387(3):482–8. Epub 2009/07/21. https://doi.org/10.1016/j.bbrc.2009.07.052 PMID: 19615974.

18. Garg P, Oikonomopoulos A, Chen H, Li Y, Lam CK, Sallam K, et al. Genome Editing of Induced Pluripotent Stem Cells to Decipher Cardiac Channelopathy Variant. J Am Coll Cardiol. 2018; 72(1):62–75. Epub 2018/06/30. https://doi.org/10.1016/j.jacc.2018.04.041 PMID: 29957233; PubMed Central PMID: PMC6050026.

19. Chavali NV, Kryshtal DO, Parikh SS, Wang L, Glazer AM, Blackwell DJ, et al. Phenotypic variability in LQT3 human induced pluripotent stem cells: the interrogative persistence and variable expressivity in heritable cardiac arrhythmia syndromes. Transl Res. 2013; 161(1):1–14. Epub 2012/09/22. https://doi.org/10.1016/j.trsl.2012.08.005 PMID: 22999532; PubMed Central PMCID: PMC3624763.

20. Giudicessi JR, Ackerman MJ. Determinants of incomplete penetrance and variable expressivity in heritable cardiac arrhythmia syndromes. Transl Res. 2013; 161(1):1–14. Epub 2012/09/22. https://doi.org/10.1016/j.trsl.2012.08.005 PMID: 22999532; PubMed Central PMCID: PMC3624763.

21. Amin AS, Pinto YM, Wilde AA. Long QT syndrome: beyond the causal mutation. J Physiol. 2013; 591(17):4125–39. Epub 2013/06/12. https://doi.org/10.1113/jphysiol.2013.279554 PMID: 23753525; PubMed Central PMCID: PMC4376422.

22. Sinnecker D, Goedel A, Dorn T, Dirschinger RJ, Moretti A, Laugwitz KL. Modeling long-QT syndromes with iPS cells. J Cardiovasc Transl Res. 2013; 6(1):31–6. https://doi.org/10.1007/s12265-012-9416-1 PMID: 23076501.

23. Yang PC, Song Y, Giles WR, Horvath B, Chen-Izu Y, Belardinelli L, et al. A computational modelling approach combined with cellular electrophysiology data provides insights into the therapeutic benefit of targeting the late Na+ current. J Physiol. 2015; 593(6):1429–42. Epub 2014/12/30. https://doi.org/10.1113/jphysiol.2014.279554 PMID: 25545172; PubMed Central PMID: PMC4376422.

24. Passini E, Britton OJ, Lu HR, Rohrbacher J, Hermans AN, Gallagher DJ, et al. Human In Silico Drug Trials Demonstrate Higher Accuracy than Animal Models in Predicting Clinical Pro-Arrhythmic Cardiotoxicity. Front Physiol. 2017; 8:668. Epub 2017/09/29. https://doi.org/10.3389/fphys.2017.00668 PMID: 28955244; PubMed Central PMID: PMC5601077.

25. Ni H, Morotti S, Grandi E. A Heart for Diversity: Simulating Variability in Cardiac Arrhythmia Research. Front Physiol. 2018; 9:958. Epub 2018/08/07. https://doi.org/10.3389/fphys.2018.00958 PMID: 30079031; PubMed Central PMID: PMC6062641.

26. Paci M, Passini E, Severi S, Hyytinien J, Rodriguez B. Phenotypic variability in LQT3 human induced pluripotent stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: An in silico approach. Heart Rhythm. 2017; 14(11):1704–12. Epub 2017/08/02. https://doi.org/10.1016/j.hrthm.2017.07.026 PMID: 28756098; PubMed Central PMID: PMC5668441.

27. Britton OJ, Bueno-Orovio A, Van Ammel K, Lu HR, Towart R, Gallagher DJ, et al. Experimentally calibrated population of models predicts and explains intersubject variability in cardiac cellular electrophysiology. Proc Natl Acad Sci U S A. 2013; 110(23):E2098–105. Epub 2013/05/22. https://doi.org/10.1073/pnas.1304382110 PMID: 23690584; PubMed Central PMID: PMC3677477.

28. Muszkiewitch A, Britton OJ, Gemmell P, Passini E, Sanchez C, Zhou X, et al. Variability in cardiac electrophysiology: Using experimentally-calibrated populations of models to move beyond the single virtual physiological human paradigm. Prog Biophys Mol Biol. 2016; 120(1–3):115–27. Epub 2015/12/25. https://doi.org/10.1016/j.pbiomolbio.2015.12.002 PMID: 26701222; PubMed Central PMID: PMC4821179.
29. Gong JQX, Sobie EA. Population-based mechanistic modeling allows for quantitative predictions of drug responses across cell types. NPJ Syst Biol Appl. 2018; 4:11. Epub 2018/03/07. https://doi.org/10.1038/s41540-018-0047-2 PMID: 29507757; PubMed Central PMCID: PMC5825396.

30. Vanoye CG, Desai RR, Fabre KL, Gallagher SL, Potet F, DeKeyser JM, et al. High-Throughput Functional Evaluation of KCNQ1 Decroixs Variants of Unknown Significance. Circ Genom Precis Med. 2018; 11(11):e002345. Epub 2018/12/21. https://doi.org/10.1161/CIRCGEN.118.002345 PMID: 30571187; PubMed Central PMCID: PMC6309341.

31. Kernik DC, Morotti S, Wu H, Garg P, Duff HJ, Kurokawa J, et al. A computational model of induced pluripotent stem-cell derived cardiomyocytes incorporating experimental variability from multiple data sources. J Physiol. 2019; 597(17):4533–64. Epub 2019/07/07. https://doi.org/10.1113/JP277724 PMID: 31278749; PubMed Central PMCID: PMC6776794.

32. Karakikes I, Stillitano F, Nonnenmacher M, Tzimas C, Sanoudou D, Termglinchel V, et al. Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nat Commun. 2015; 6:6955. Epub 2015/04/30. https://doi.org/10.1038/ncomms7955 PMID: 25923014; PubMed Central PMCID: PMC4421839.

33. Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018; 46(D1):D1062–D7. Epub 2018/03/14. https://doi.org/10.1002/nbg.9533 PMID: 29532034; PubMed Central PMCID: PMC5842040.

34. Lancaster MC, Sobie EA. Improved Prediction of Drug-Induced Torsades de Pointes Through Simulations of Dynamics and Machine Learning Algorithms. Clin Pharmacol Ther. 2016; 100(4):371–9. Epub 2016/03/08. https://doi.org/10.1002/cpt.367 PMID: 26950176; PubMed Central PMCID: PMC6375298.

35. Hondegheim LM, Carlsson L, Duker G. Instability and triangulation of the action potentia l predict serious arrhythmias. Circ Res. 2016; 119(14):1882–92. Epub 2016/03/08. https://doi.org/10.1161/CIRCRESAHA.115.306119 PMID: 27006372.

36. Priori SG, Schwartz PJ, Napolitano C, Bianchi L, De Fusco M, et al. A recessive variant of the SCN5A channel causes short QT syndrome due to a new S5 segment mutation. Circ Res. 2013; 112(6):951–5. Epub 2013/03/06. https://doi.org/10.1161/CIRCRESAHA.112.221889.

37. Li M, Kanda Y, Ashihara T, Sasano T, Nakai Y, Kodama M, et al. Overexpression of KCNJ2 in induced pluripotent stem cells results in familial long QT syndrome type 1. PLoS Genet. 2014; 10(1):e1004010. Epub 2013/12/04. https://doi.org/10.1371/journal.pgen.1004010 PMID: 24845848; PubMed Central PMCID: PMC3851822.

38. Moreno C, Oliveras A, de la Cruz A, Bartolucci C, Munoz C, Salar E, et al. A new KCNQ1 mutation at the S5 segment that impairs its association with KCNE1 is responsible for short QT syndrome. Cardiovasc Res. 2015; 107(4):613–23. Epub 2015/07/15. https://doi.org/10.1093/cvr/cvr196 PMID: 26168993.

39. Goverlsen B, van der Heyden MAG, van Veen TAB, de Boer TP. The immature electrophysiological phenotype of iPSC-CMs still hampers in vitro drug screening: Special focus on IK1. Pharmaco Ther. 2018; 183:127–36. Epub 2017/10/08. https://doi.org/10.1016/j.ijpharmther.2017.10.001 PMID: 28986101.

40. Li M, Kanda Y, Ashihara T, Sasano T, Nakai Y, Kodama M, et al. Overexpression of KCNJ2 in induced pluripotent stem cell-derived cardiomyocytes for the assessment of QT-prolonging drugs. J Pharmacol Sci. 2017; 134(2):75–85. https://doi.org/10.1016/j.jphs.2017.05.004 PMID: 28615142.

41. Bett GC, Kaplan AD, Lis A, Cimato TR, Tzanakakis ES, Zhou Q, et al. Electronic “expression” of the inward rectifier in cardiocytes derived from human-induced pluripotent stem cells. Heart Rhythm. 2013; 10(12):1903–10. Epub 2013/09/24. https://doi.org/10.1016/j.hrthm.2013.09.061 PMID: 24055949; PubMed Central PMCID: PMC3851822.

42. Huang H, Kuenze G, Smith JA, Taylor KC, Duran AM, Hadziselimovic A, et al. Mechanisms of KCNQ1 channel dysfunction in long QT syndrome involving voltage sensor domain mutations. Sci Adv. 2018; 4(3):eaar2631. Epub 2018/03/14. https://doi.org/10.1126/sciadv.aar2631 PMID: 29532034; PubMed Central PMCID: PMC5842040.

43. Clemens DJ, Lentino AR, Kaplinger JD, Ye D, Zhou W, Tester DJ, et al. Using the genome aggregation database, computational pathogenicity prediction tools, and patch clamp heterologous expression studies to demote previously published long QT syndrome type 1 mutations from pathogenic to benign. Heart Rhythm. 2018; 15(4):555–61. Epub 2017/12/05. https://doi.org/10.1016/j.hrthm.2017.11.032 PMID: 29197658; PubMed Central PMCID: PMC5838800.

44. National Center for Biotechnology Information. ClinVar [cited 2020 January 28].

45. Tester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm. 2005; 2(5):507–17. Epub 2005/04/21. https://doi.org/10.1016/j.hrthm.2005.01.020 PMID: 15840476.
46. Hammami Bornholtz S, Refaat M, Buur Steffensen A, David JP, Espinosa K, Nuusbaum R, et al. Functional phenotype variations of two novel KV 7.1 mutations identified in patients with Long QT syndrome. Pacing Clin Electrophysiol. 2020;132(2):379–86. Epub 2020/09/03. https://doi.org/10.1161/PACE.119.328410; PubMed Central PMCID: PMC6752438.

47. Zareba W, Moss AJ, Sheu G, Kaufman ES, Priori S, Vincent GM, et al. Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrome. J Cardiovasc Electrophysiol. 2003; 14 (11):1149–53. Epub 2003/12/18. https://doi.org/10.1046/j.1540-8167.2003.00317.x; PMID: 14678125.

48. Zhang X, Chen S, Zhang L, Liu M, Redfearn S, Bryant RM, et al. Protective effect of KCNH2 single nucleotide polymorphism K897T in LQTS families and identification of novel KCNQ1 and KCNH2 mutations. BMC Med Genet. 2008; 9:87. Epub 2008/09/24. https://doi.org/10.1186/1471-2350-9-87; PMID: 18808722; PubMed Central PMCID: PMC2507672.

49. Milos P, Manik-Seymour A, Richmond J, Power A. Methods & compositions relating to drug-induced arrhythmia. Google Patents; 2005.

50. Mann SA, Irntiazi M, Winbo A, Rhydberg A, Perry MD, Couderc JP, et al. Convergence of models of human ventricular myocyte electrophysiology after global optimization to recapitulate clinical long QT phenotypes. J Mol Cell Cardiol. 2016; 100:25–34. Epub 2016/10/25. https://doi.org/10.1016/j.ymcelin.2016.09.011; PMID: 27663173.

51. O’Hara T, Virag L, Varro A, Rudy Y. Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. PLoS Comput Biol. 2011; 7(5):e1002061. https://doi.org/10.1371/journal.pcbi.1002061; PMID: 21637795; PubMed Central PMCID: PMC3102752.

52. O’Hara T, Rudy Y. Arrhythmia formation in subclinical ("silent") long QT syndrome requires multiple insults: quantitative mechanistic study using the KCNQ1 mutation Q357R as example. Heart Rhythm. 2012; 9(2):275–82. Epub 2011/09/29. https://doi.org/10.1016/j.hrthm.2011.09.066; PMID: 21952006; PubMed Central PMCID: PMC3443981.

53. Ackerman JP, Bartos DC, Kapplinger JD, Tester DJ, Delisle BP, Ackerman MJ. The Promise and Peril of Precision Medicine: Phenotyping Still Matters Most. Mayo Clin Proc. 2016. Epub 2016/11/05. https://doi.org/10.1016/j.mayocp.2016.08.008; PMID: 27810088; PubMed Central PMCID: PMC6365209.

54. Donger C, Denjoy I, Berthet M, Neyroud N, Bennaceur M, et al. KVLT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation. 1997; 96(9):2778–81. Epub 1997/12/31. https://doi.org/10.1161/01.cir.96.9.2778; PMID: 9386136.

55. Lane CM, Giudicessi JR, Ye D, Tester DJ, Rohatgi RK, Bos JM, et al. Long QT syndrome type 5-Lite: Defining the clinical phenotype associated with the potentially proarrhythmic p.Asp85Asn-KCNE1 common variant. Heart Rhythm. 2018; 15(8):1223–30. Epub 2018/04/07. https://doi.org/10.1016/j.hrthm.2018.03.038; PMID: 29625280; PubMed Central PMCID: PMC6402333.

56. Kapplinger JD, Erickson A, Asuri S, Tester DJ, McIntosh S, Kerr CR, et al. KCNQ1 p.L3S53L affects splicing and modifies the phenotype in a founder population with long QT syndrome type 1. J Med Genet. 2017; 54(6):390–8. Epub 2017/03/08. https://doi.org/10.1136/jmedgenet-2016-104153; PMID: 28264985; PubMed Central PMCID: PMC5502312.

57. Earle N, Yeo Han D, Pilbrow A, Crawford J, Smith W, Shelling AN, et al. Single nucleotide polymorphisms in arrhythmia genes modify the risk of cardiac events and sudden death in long QT syndrome. Heart Rhythm. 2014; 11(1):76–82. Epub 2013/10/08. https://doi.org/10.1016/j.hrthm.2013.10.005; PMID: 24096169.

58. Jennewein T, Neumann T, Erkapic D, Kuniss M, Verhoff MA, Thiel G, et al. Influence of genetic modifiers on sudden cardiac death cases. Int J Legal Med. 2018; 132(2):379–85. Epub 2017/12/08. https://doi.org/10.1007/s00414-017-1739-7; PMID: 29214556.

59. Crotti L, Monti MC, Insolia R, Pelitto A, Goosen A, Brink PA, et al. NOS1AP is a genetic modifier of the long-QT syndrome. Circulation. 2009; 120(17):1657–63. Epub 2009/10/14. https://doi.org/10.1161/CIRCULATIONAHA.109.879643; PMID: 19822806; PubMed Central PMCID: PMC2783481.

60. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation. 1999; 99(4):529–33. Epub 1999/09/14. https://doi.org/10.1161/01.cir.99.4.529; PMID: 9927399.

61. Itch H, Crotti L, Alba T, Spazzolini C, Denjoy I, Fressart V, et al. The genetics underlying acquired long QT syndrome: impact for genetic screening. Eur Heart J. 2016; 37(18):1456–64. Epub 2015/12/31. https://doi.org/10.1093/eurheartj/ehw695; PMID: 26715165; PubMed Central PMCID: PMC4914885.

62. Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A. 2000; 97(19):10613–8. Epub 2000/09/14. https://doi.org/10.1073/pnas.180223197; PMID: 10984545; PubMed Central PMCID: PMC270737.

63. Paulussen AD, Gilissen RA, Armstrong M, Doevendans PA, Verhasselt P, Smeets HJ, et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome.
patients. J Mol Med (Berl). 2004; 82(3):182–8. Epub 2004/02/05. https://doi.org/10.1007/s00109-003-0522-z PMID: 14760488.

64. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002; 105(16):1943–8. Epub 2002/05/09. https://doi.org/10.1161/01.cir.0000014448.19052.4c PMID: 11997281.

65. Romero L, Trenor B, Yang PC, Saiz J, Clancy CE. In silico screening of the impact of HERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome. J Mol Cell Cardiol. 2015; 87:271–82. Epub 2016/02/10. https://doi.org/10.1016/j.yjmcc.2015.08.015 PMID: 26859003; PubMed Central PMCID: PMC4935925.

66. Viswanathan PC, Rudy Y. Cellular arrhythmogenic effects of congenital and acquired long-QT syndrome in the heterogeneous myocardiun. Circulation. 2000; 101(10):1192–8. Epub 2000/03/15. https://doi.org/10.1161/01.cir.101.10.1192 PMID: 10715268.

67. Cooper DN, Krawczak M, Polychronakos C, Tyler-Smith C, Kehrer-Sawatzki H. Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease. Hum Genet. 2013; 132(10):1077–130. Epub 2013/07/04. https://doi.org/10.1007/s00439-013-1331-2 PMID: 23820649; PubMed Central PMCID: PMC3778950.

68. Mullally J, Goldenberg I, Moss AJ, Lopes CM, Ackerman MJ, Zareba W, et al. Risk of life-threatening cardiac events among patients with long QT syndrome and multiple mutations. Heart Rhythm. 2013; 10(3):378–82. Epub 2012/11/24. https://doi.org/10.1016/j.hrthm.2012.11.006 PMID: 23174487; PubMed Central PMCID: PMC3690288.

69. Heijman J, Volders PG, Westra RL, Rudy Y. Local control of beta-adrenergic stimulation: Effects on ventricular myocyte electrophysiology and Ca(2+)-transient. J Mol Cell Cardiol. 2011; 50(5):863–71. Epub 2011/02/25. https://doi.org/10.1016/j.yjmcc.2011.02.007 PMID: 21345340; PubMed Central PMCID: PMC3075371.

70. Gong JQX, Susilo ME, Sher A, Musante CJ, Sobie EA. Quantitative analysis of variability in an integrated model of human ventricular electrophysiology and beta-adrenergic signaling. J Mol Cell Cardiol. 2020; 143:96–106. Epub 2020/04/25. https://doi.org/10.1016/j.yjmcc.2020.04.009 PMID: 32330487.

71. Yoshinaga D, Baba S, Makiyama T, Shibata H, Hirata T, Akagi K, et al. Phenotype-Based High-Throughput Classification of Long QT Syndrome Subtypes Using Human Induced Pluripotent Stem Cells. Stem Cell Reports. 2020; 14(3):394–404. Epub 2019/08/06. https://doi.org/10.1016/j.stemcr.2019.06.007 PMID: 31378668; PubMed Central PMCID: PMC6700479.

72. Blinova K, Stohlman J, Vicente J, Chan D, Johannessen L, Hortiger-Vinagre MP, et al. Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias. Toxicol Sci. 2017; 155(1):234–47. Epub 2016/10/05. https://doi.org/10.1093/toxsci/kfw200 PMID: 27701120; PubMed Central PMCID: PMC6093617.

73. Karakikes I, Ameen M, Termglinchan V, Wu JC. Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes. Circ Res. 2015; 117(1):80–8. Epub 2015/06/20. https://doi.org/10.1161/CIRCRESAHA.117.305365 PMID: 26089365; PubMed Central PMCID: PMC4546707.

74. Tanskanen AJ, Alvarez LH. Voltage noise influences action potential duration in cardiac myocytes. Math Biosci. 2007; 208(1):125–46. Epub 2006/12/19. https://doi.org/10.1016/j.mbs.2006.09.023 PMID: 17174348; PubMed Central PMCID: PMC2568901.